Retrospective Study: Hospitalizations, Mortaity Cut In Half After Brazilian City Offered Ivermectin

Hospitalizations, Mortality Cut In Half After Brazilian City Offered Ivermectin To Everyone Pre-Vaccine

TYLER DURDEN

Early on in the pandemic, before the vaccines were available, the Southern Brazilian city of Itajai offered Ivermectin as a prophylaxis against the disease.

Between July and December of 2020, roughly 220,000 people were offered a dose of 0.2mg/kg/day (roughly 18mg for a 200lb person) as an optional treatment for 2 days, once every two weeks.

133,051 people took them up on it, while 87,466 did not.

After analyzing the data, a team of researchers spanning several Brazilian institutes, the University of Toronto, and Columbia's EAFIT concluded in a December pre-print study that hospitalization and mortality rates were cut in half over the seven month period among the Ivermectin group.

This is even more impressive when you learn the IVM users were older on average, with 30% >50 yo versus 20% for non-IVM users. The mortality reduction is even higher looking at different age groups. 85% for 31-49 yo and 59% for >50 yo.

The authors adjusted for relevant confounding variables, including age, sex, medical history, previous diseases, and other conditions.

The analysis contradicts an October report by Business Insider which claims, based on a Brazilian ICU doctor's anecdotal evidence, that the experiment was a failure.

Separately, there have been several studies funded by the Indian government, primarily conducted through their largest govt. public medical university (AIIMS).

• Role of ivermectin in the prevention of SARS-CoV-2 infection among healthcare workers in India: A matched case-control study (source)

Conclusion: Two-dose ivermectin prophylaxis at a dose of 300 μg/kg with a gap of 72 hours was associated with a 73% reduction of SARS-CoV-2 infection among healthcare workers for the following month.

• Ivermectin as a potential treatment for mild to moderate COVID-19 – A double blind randomized placebo-controlled trial (source)

Conclusion: There was no difference in the primary outcome i.e. negative RT-PCR status on day 6 of admission with the use of ivermectin. However, a significantly higher proportion of patients were discharged alive from the hospital when they received ivermectin. 

• Clinical Research Report Ivermectin in combination with doxycycline for treating COVID-19 symptoms: a randomized trial (source, double-blind randomized, peer-reviewed)

Discussion: In the present study, patients with mild or moderate COVID-19 infection treated with ivermectin in combination with doxycycline generally recovered 2 days earlier than those treated with placebo. The proportion of patients responding within 7 days of treatment was significantly higher in the treatment group than in the placebo group. The proportions of patients who remained symptomatic after 12 days of illness and who experienced disease progression were significantly lower in the treatment group than in the placebo group.

 

More...